Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087849 · ClinicalTrials.gov registry record · Phase 1
Intralesional HPV Vaccine for Condylomata
A Phase 1 study of Human Papilloma Virus and Warts, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT05087849 is a Phase 1 study of Human Papilloma Virus and Warts that has completed, run by University of California, San Francisco. The registered enrollment target is 2 participants, below the 624-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05087849, a Phase 1 study of Human Papilloma Virus and Warts, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
Conditions Studied
Interventions
- BIOLOGICAL nonavalent human papillomavirus vaccine
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05087849
The ClinicalTrials.gov registry entry for NCT05087849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 624-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which nonavalent human papillomavirus vaccine is the first listed.
NCT05087849 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05087849 about?
NCT05087849 is a clinical study titled "Intralesional HPV Vaccine for Condylomata". This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.
What is the current status of trial NCT05087849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-04-15. Estimated completion is 2024-07-01.
What conditions does trial NCT05087849 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Warts, Condylomata Acuminata, Warts, Genital, Condyloma.
What interventions are being tested in trial NCT05087849?
The interventions under investigation include: nonavalent human papillomavirus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05087849?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05087849 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
RECRUITING · Phase 1
-
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
COMPLETED · Phase 1
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.